FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2121050884> ?p ?o ?g. }

• W2121050884 endingPage "1620" @default.
• W2121050884 startingPage "1613" @default.
• W2121050884 abstract "<h3>Objectives</h3> To compare the efficacy and safety of innovator infliximab (INX) and CT-P13, an INX biosimilar, in active rheumatoid arthritis patients with inadequate response to methotrexate (MTX) treatment. <h3>Methods</h3> Phase III randomised, double-blind, multicentre, multinational, parallel-group study. Patients with active disease despite MTX (12.5–25 mg/week) were randomised to receive 3 mg/kg of CT-P13 (n=302) or INX (n=304) with MTX and folic acid. The primary endpoint was the American College of Rheumatology 20% (ACR20) response at week 30. Therapeutic equivalence of clinical response according to ACR20 criteria was concluded if the 95% CI for the treatment difference was within ±15%. Secondary endpoints included ACR response criteria, European League Against Rheumatism (EULAR) response criteria, change in Disease Activity Score 28 (DAS28), Medical Outcomes Study Short-Form Health Survey (SF-36), Simplified Disease Activity Index, Clinical Disease Activity Index, as well as pharmacokinetic (PK) and pharmacodynamic (PD) parameters, safety and immunogenicity. <h3>Results</h3> At week 30, ACR20 responses were 60.9% for CT-P13 and 58.6% for INX (95% CI −6% to 10%) in the intention-to-treat population. The proportions in CT-P13 and INX groups achieving good or moderate EULAR responses (C reactive protein (CRP)) at week 30 were 85.8% and 87.1%, respectively. Low disease activity or remission according to DAS28–CRP, ACR–EULAR remission rates, ACR50/ACR70 responses and all other PK and PD endpoints were highly similar at week 30. Incidence of drug-related adverse events (35.2% vs 35.9%) and detection of antidrug antibodies (48.4% vs 48.2%) were highly similar for CT-P13 and INX, respectively. <h3>Conclusions</h3> CT-P13 demonstrated equivalent efficacy to INX at week 30, with a comparable PK profile and immunogenicity. CT-P13 was well tolerated, with a safety profile comparable with that of INX. <h3>ClinicalTrials.gov Identifier</h3> NCT01217086" @default.
• W2121050884 created "2016-06-24" @default.
• W2121050884 creator A5003041238 @default.
• W2121050884 creator A5007653414 @default.
• W2121050884 creator A5015800123 @default.
• W2121050884 creator A5020978466 @default.
• W2121050884 creator A5036530922 @default.
• W2121050884 creator A5041319130 @default.
• W2121050884 creator A5044949180 @default.
• W2121050884 creator A5045593530 @default.
• W2121050884 creator A5050596110 @default.
• W2121050884 creator A5052206707 @default.
• W2121050884 creator A5064707258 @default.
• W2121050884 creator A5066408904 @default.
• W2121050884 creator A5076995360 @default.
• W2121050884 creator A5081428280 @default.
• W2121050884 creator A5082275964 @default.
• W2121050884 creator A5083955728 @default.
• W2121050884 creator A5088115834 @default.
• W2121050884 creator A5090693306 @default.
• W2121050884 date "2013-05-16" @default.
• W2121050884 modified "2023-10-17" @default.
• W2121050884 title "A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study" @default.
• W2121050884 cites W1985763670 @default.
• W2121050884 cites W1994065448 @default.
• W2121050884 cites W1996437423 @default.
• W2121050884 cites W1999777294 @default.
• W2121050884 cites W2000962647 @default.
• W2121050884 cites W2097341637 @default.
• W2121050884 cites W2111046066 @default.
• W2121050884 cites W2114777614 @default.
• W2121050884 cites W2128918690 @default.
• W2121050884 cites W2151367268 @default.
• W2121050884 cites W2166771071 @default.
• W2121050884 cites W4295125684 @default.
• W2121050884 doi "https://doi.org/10.1136/annrheumdis-2012-203090" @default.
• W2121050884 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3786641" @default.
• W2121050884 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23687260" @default.
• W2121050884 hasPublicationYear "2013" @default.
• W2121050884 type Work @default.
• W2121050884 sameAs 2121050884 @default.
• W2121050884 citedByCount "568" @default.
• W2121050884 countsByYear W21210508842012 @default.
• W2121050884 countsByYear W21210508842013 @default.
• W2121050884 countsByYear W21210508842014 @default.
• W2121050884 countsByYear W21210508842015 @default.
• W2121050884 countsByYear W21210508842016 @default.
• W2121050884 countsByYear W21210508842017 @default.
• W2121050884 countsByYear W21210508842018 @default.
• W2121050884 countsByYear W21210508842019 @default.
• W2121050884 countsByYear W21210508842020 @default.
• W2121050884 countsByYear W21210508842021 @default.
• W2121050884 countsByYear W21210508842022 @default.
• W2121050884 countsByYear W21210508842023 @default.
• W2121050884 crossrefType "journal-article" @default.
• W2121050884 hasAuthorship W2121050884A5003041238 @default.
• W2121050884 hasAuthorship W2121050884A5007653414 @default.
• W2121050884 hasAuthorship W2121050884A5015800123 @default.
• W2121050884 hasAuthorship W2121050884A5020978466 @default.
• W2121050884 hasAuthorship W2121050884A5036530922 @default.
• W2121050884 hasAuthorship W2121050884A5041319130 @default.
• W2121050884 hasAuthorship W2121050884A5044949180 @default.
• W2121050884 hasAuthorship W2121050884A5045593530 @default.
• W2121050884 hasAuthorship W2121050884A5050596110 @default.
• W2121050884 hasAuthorship W2121050884A5052206707 @default.
• W2121050884 hasAuthorship W2121050884A5064707258 @default.
• W2121050884 hasAuthorship W2121050884A5066408904 @default.
• W2121050884 hasAuthorship W2121050884A5076995360 @default.
• W2121050884 hasAuthorship W2121050884A5081428280 @default.
• W2121050884 hasAuthorship W2121050884A5082275964 @default.
• W2121050884 hasAuthorship W2121050884A5083955728 @default.
• W2121050884 hasAuthorship W2121050884A5088115834 @default.
• W2121050884 hasAuthorship W2121050884A5090693306 @default.
• W2121050884 hasBestOaLocation W21210508841 @default.
• W2121050884 hasConcept C111113717 @default.
• W2121050884 hasConcept C112705442 @default.
• W2121050884 hasConcept C126322002 @default.
• W2121050884 hasConcept C1862650 @default.
• W2121050884 hasConcept C197934379 @default.
• W2121050884 hasConcept C198451711 @default.
• W2121050884 hasConcept C203092338 @default.
• W2121050884 hasConcept C2777138892 @default.
• W2121050884 hasConcept C2777489490 @default.
• W2121050884 hasConcept C2777575956 @default.
• W2121050884 hasConcept C2779134260 @default.
• W2121050884 hasConcept C2781059491 @default.
• W2121050884 hasConcept C535046627 @default.
• W2121050884 hasConcept C71924100 @default.
• W2121050884 hasConcept C90924648 @default.
• W2121050884 hasConceptScore W2121050884C111113717 @default.
• W2121050884 hasConceptScore W2121050884C112705442 @default.
• W2121050884 hasConceptScore W2121050884C126322002 @default.
• W2121050884 hasConceptScore W2121050884C1862650 @default.
• W2121050884 hasConceptScore W2121050884C197934379 @default.
• W2121050884 hasConceptScore W2121050884C198451711 @default.
• W2121050884 hasConceptScore W2121050884C203092338 @default.
• W2121050884 hasConceptScore W2121050884C2777138892 @default.
• W2121050884 hasConceptScore W2121050884C2777489490 @default.

• next